A summary of our approach to extramedullary disease
| MS development . | Extent of involvement . | Strategies . |
|---|---|---|
| Initial | Isolated | Intensive AML chemotherapy with consideration of RT as consolidation |
| Concurrent MS and marrow | Intensive AML chemotherapy with consideration of HCT; RT if MS persists after induction chemotherapy | |
| Relapse | Isolated | |
| After chemotherapy | Reinduction AML chemotherapy with consideration of HCT | |
| After transplant | Donor lymphocyte infusion, tapering of immunosuppression, RT, and/or clinical trial | |
| MS and marrow | ||
| After chemotherapy | Reinduction AML chemotherapy with consideration of HCT, RT, and/or clinical trial | |
| LC | Marrow status | Strategies |
| Negative | Intensive AML chemotherapy | |
| AML | Intensive AML chemotherapy with consideration of HCT; TSEB after chemotherapy for persistent LC if marrow negative |
| MS development . | Extent of involvement . | Strategies . |
|---|---|---|
| Initial | Isolated | Intensive AML chemotherapy with consideration of RT as consolidation |
| Concurrent MS and marrow | Intensive AML chemotherapy with consideration of HCT; RT if MS persists after induction chemotherapy | |
| Relapse | Isolated | |
| After chemotherapy | Reinduction AML chemotherapy with consideration of HCT | |
| After transplant | Donor lymphocyte infusion, tapering of immunosuppression, RT, and/or clinical trial | |
| MS and marrow | ||
| After chemotherapy | Reinduction AML chemotherapy with consideration of HCT, RT, and/or clinical trial | |
| LC | Marrow status | Strategies |
| Negative | Intensive AML chemotherapy | |
| AML | Intensive AML chemotherapy with consideration of HCT; TSEB after chemotherapy for persistent LC if marrow negative |
TSEB indicates total skin electron beam therapy.